Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28116366 | 0.89 | RIPK1 (0.58) | HIF1AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL21523774 | 0.84 | HIF1A (0.47) | HIF1AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL21523602 | 0.83 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1HTTGAA | |
| SCHEMBL21523675 | 0.82 | SCD5 (0.45) | HIF1AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL21523770 | 0.80 | LMNA (0.58) | HIF1AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL23388368 | 0.80 | F2 (0.43) | HIF1AMEN1KMT2AALDH1A1RIPK1 | |
| SCHEMBL21523794 | 0.78 | KMT2A (0.58) | MEN1KMT2AALDH1A1HTTGAA | |
| SCHEMBL19252939 | 0.76 | MAPT (0.68) | MEN1KMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL17166119 | 0.75 | POLB (0.45) | HIF1AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL22619675 | 0.74 | HIF1A (0.46) | HIF1AMEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620950-A | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109071542-B | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3848373-A1 | N-(1-((HETEROCYCLYL)METHYL)-1H-PYRAZOL-4-YL)-6-OXO-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[L,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | Phoenix Molecular Designs (CA) | 2021-07-14 | — | — | EP | disclosed |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2021-06-24 | — | — | US | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2019-05-09 | — | — | US | disclosed |
| EP-3416964-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | Phoenix Molecular Designs (CA) | 2018-12-26 | — | — | EP | disclosed |
| CN-109071542-A | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | 凤凰分子设计公司 | 2018-12-21 | — | — | CN | disclosed |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2018-09-25 | — | — | US | disclosed |
| US-20170327501-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-11-16 | — | — | US | disclosed |
| US-20170327501-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-11-16 | — | — | US | disclosed |
| US-9771366-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGN (CA) | 2017-09-26 | — | — | US | disclosed |
| US-9771366-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGN (CA) | 2017-09-26 | — | — | US | disclosed |
| US-9771366-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGN (CA) | 2017-09-26 | — | — | US | disclosed |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | US | disclosed |
| WO-2017141116-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | US | disclosed |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | US | disclosed |
| WO-2017141116-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | HIF1A 1867/4885MEN1 3975/4885KMT2A 1496/4885 |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | HIF1A 2526/4885MEN1 4581/4885KMT2A 2483/4885 |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | RPS6KA2, RPS6KA5, RPS6KA1 | HIF1A 2714/4885MEN1 4300/4885KMT2A 1804/4885 |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | RPS6KA5, RPS6KA2, RPS6KA1 | HIF1A 1867/4885MEN1 3975/4885KMT2A 1496/4885 |
| US-20170327501-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | HIF1A 2162/4885MEN1 4381/4885KMT2A 1710/4885 |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | HIF1A 2162/4885MEN1 4381/4885KMT2A 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.